Drugs / SSS68
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07606976 | Jun → Dec 2026 expected | — | Shenyang Sunshine Pharmaceutical Co., LTD. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SSS68 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07606976 ↗ |
| Route | Subcutaneous | “A single dose of SSS68 will be administered SC on Day 1.” NCT07606976 ↗ |